Susquehanna International Group, LLP Entrada Therapeutics, Inc. Transaction History
Susquehanna International Group, LLP
- $688 Billion
- Q2 2025
A detailed history of Susquehanna International Group, LLP transactions in Entrada Therapeutics, Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 36,815 shares of TRDA stock, worth $223,098. This represents 0.0% of its overall portfolio holdings.
Number of Shares
36,815
Previous 31,960
15.19%
Holding current value
$223,098
Previous $288,000
14.24%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding TRDA
# of Institutions
107Shares Held
28.8MCall Options Held
15.7KPut Options Held
0-
Baker Bros. Advisors LP New York, NY4.87MShares$29.5 Million0.33% of portfolio
-
Mpm Asset Management LLC Cambridge, MA4.38MShares$26.5 Million67.92% of portfolio
-
5 Am Venture Management, LLC San Francisco, CA4.31MShares$26.1 Million19.43% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.57MShares$15.6 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.69MShares$10.3 Million0.0% of portfolio
About Entrada Therapeutics, Inc.
- Ticker TRDA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 31,368,500
- Market Cap $190M
- Description
- Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in precli...